Our results are in line with the study conducted by Wargny et al. who reported no significant associations between PCSK9 and transaminases in hepatic steatosis and NASH in high-risk patients with coexisting DM type 2 and obesity [52]. The gene discussed is PCSK9; the disease is obesity due to melanocortin 4 receptor deficiency.